Topigen Pharmaceuticals Inc.
This article was originally published in Start Up
Topigen Pharmaceuticals Inc. plans to mount a full-scale attack on chronic respiratory ailments such as asthma, COPD and allergic rhinitis, with mRNA-interfering drugs that target multiple pathways. Its lead compound, for asthma, combines two antisense molecules to target at least eight different components of the inflammatory response.
You may also be interested in...
Asthma represents one of the blockbuster markets in the pharmaceutical industry; sales of drugs from 10 companies amount to $14 billion each year. Yet despite the high-volume sales of asthma drugs, in 73% of patients the disease is poorly controlled. For pharmaceutical firms and start-ups, the complex, multifactorial disease offers tantalizing possibilities; it's an enormous, yet underserved market with many points of entry, mechanistically speaking.
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.